| 引用本文:袁丽莎1，魏宇2，曹钋2，钟剑2，王京2，裴志行1，宋雅丽2，豆芳梅2.补肾健脾生血法治疗维持性血液透析肾性贫血疗效及安全性的Meta分析[J].世界中医药,2019,(10):. |
|
| 补肾健脾生血法治疗维持性血液透析肾性贫血疗效及安全性的Meta分析 |
| Efficacy and Safety of Bushen Jianpi Shengxue Therapy in the Treatment of Maintenance Hemodialysis with Renal Anemia：A Meta-analysis |
| 投稿时间：2019-02-25 |
| DOI：10.3969/j.issn.1673-7202.2019.10.021 |
| 中文关键词: 血液透析 肾性贫血 补肾健脾生血法 促红细胞生成素 Meta分析 |
| English Keywords:Hemodialysis Renal anemia Bushen Jianpi Shengxue Method Erythropoietin Meta-analysis |
| 基金项目:北京中医药大学基本科研业务费项目(青年教师项目)(2018-JYB-JS086) |
|
| 摘要点击次数: 571 |
| 全文下载次数: 750 |
| 中文摘要: |
| 目的:系统评价补肾健脾生血法联合促红细胞生成素(Erythropoietin,EPO)治疗维持性血液透析(Maintenance Hemodialysis,MHD)肾性贫血的疗效及安全性。方法:计算机检索中国期刊全文数据库、万方数据知识服务平台、维普中文科技期刊数据库、中国生物医学文献数据库、PubMed、Cochrane Library、EMBase、Web of Science数据库,由两名研究者单独筛选文献、提取资料。采用RevMan 5.3软件进行Meta分析,采用Cochrane偏倚风险评估工具对纳入文献进行质量评价。结果:共纳入13篇随机对照试验,共855例MHD肾性贫血患者。Meta分析结果显示,观察组血红蛋白水平[均数差(MD)=9.52,95%CI(6.75,12.29),P<0.000 01]、红细胞压积水平[均数差(MD)=0.79,95%CI(0.33,1.24),P=0.000 7]、血清铁蛋白水平[均数差(MD)=8.71,95%CI(4.54,12.88),P<0.000 1]高于对照组,差异有统计学意义。观察组血尿素氮水平[均数差(MD)=-3.79,95%CI(-6.92,-0.65),P=0.02]、血肌酐水平[均数差(MD)=-80.84,95%CI(-154.53,-7.15),P=0.03]低于对照组,差异有统计学意义。观察组总不良反应发生率低于对照组,差异无统计学意义[RR=0.30,95%CI(0.09,1.02),P=0.05],其中观察组高血压不良反应发生率低于对照组,差异有统计学意义[RR=0.28,95%CI(0.10,0.77),P=0.01]。结论:基于目前证据,对于MHD肾性贫血的治疗,以补肾健脾生血法为主的中药联合EPO治疗比单纯应用EPO治疗能更好地升高血红蛋白、红细胞压积和铁蛋白水平,降低尿素氮和肌酐水平,且高血压不良反应发生率更低,安全性更好。 |
| English Summary: |
| To evaluate the efficacy and safety of Bushen Jianpi Shengxue Therapy combined with erythropoietin(EPO)in the treatment of maintenance hemodialysis(MHD)with renal anemia.Methods:We searched CNKI，Wanfang Data，VIP，CBM，PubMed，Cochrane Library，Embase and Web of Science database for studies evaluating the efficacy and safety of Bushen Jianpi Shengxue therapy for MHD Renal anemia.Studies screening and data extraction were performed by 2 researchers separately.Meta-analysis was conducted with RevMan 5.3.The quality of the included literature was evaluated using the Cochrane bias risk assessment tool.Results:A total of 13 randomized controlled trials involving 855 individuals with MHD renal anemia were included.Meta-analysis showed that the treatment group demonstrated much higher levels of the mean hemoglobin[mean difference(MD)=9.52，95% CI(6.75，12.29)，P<0.000 01]，mean Hct[mean difference(MD)=0.99，95% CI(0.33)，1.24)，P=0.000 7]，mean serum ferritin level[mean difference(MD)=8.71，95% CI(4.54，12.88)，P<0.000 1]compared with the control group.The treatment group demonstrated much lower levels of the mean blood urea nitrogen[mean difference(MD)=-3.99，95% CI（-6.92，-0.65)，P=0.02]，mean serum creatinine level(mean difference(MD)=-80.84，95% CI（-154.53，-7.15)，P=0.03]compared with the control group.The incidence of total adverse reactions in the treatment group was lower than that in the control group，and the difference was not statistically significant(RR=0.30，95%CI(0.09，1.02)，P=0.05).The incidence of hypertension in the treatment group was much lower than that in the control group[RR=0.28，95% CI(0.10，0.77)，P=0.01].Conclusion:Our analysis found that for the treatment of MHD renal anemia，traditional Chinese medicine of Bushen Jianpi Shengxue method combined with EPO treatment can increase Hb，Hct，SF and reduce urea nitrogen and serum creatinine better than EPO alone，at the same time，the incidence of adverse reactions to hypertension is lower，with better safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
